Skip to main content

Advertisement

Table 3 Overview of assumed clinical parameters for DVT and/or PE patients

From: Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist

Probability, mean (SE) DVT patients PE patients Source
Event/outcome    
Incidence of recurrent VTE (HR) 0.68 (0.218) 1.123 (0.207) *
Incidence of major bleeding (HR) 0.646 (0.242) 0.493 (0.24) *
Incidence of NMCR bleeding (RR) 1.055 (0.123) 1.001 (0.088) *
Probability that a recurrent VTE is a DVT 0.483 (0.054) 0.372 (0.050) *
Probability that a major bleeding event is a (major) IC bleed 0.125 (0.058) 0.143 (0.076) *
Discontinuation    
Patients with IC bleeding events 1.00 (0.0) 1.00 (0.0) *
Patients with major EC bleeding events 0.400 (0.089) 0.164 (0.045) *
Patients with NMCR bleeding events 0.110 (0.020) 0.054 (0.010) *
For any other reason (additional) 3–12 months 0.019 (0.001) 0.021 (0.001) *
For any other reason (additional) >12 months 0.036 (0.013) 0.036 (0.013) Boggon 2011 [62]
  DVT and PE patients  
Risks of subsequent morbidities
Recurrent VTE (per 3-month time step) 0.013 (0.074) Prandoni 2007 [41]
Progression to CTEPH after a PE 0.013 (0.002) Miniati 2006 [38]
Cumulative incidence of severe PTS (to 1 year) 0.027 (0.007) Prandoni 1997 [40]
Cumulative incidence of severe PTS (to 5 years) 0.081 (0.012) Prandoni 1997 [40]
Mortality associated with another model event
PE (during acute treatment phase) 0.250 (0.041) *
PE (after acute treatment phase) 0.331 (0.041) Prandoni 1997 [40]
Major IC bleeding 0.436 (0.036) Linkins 2010 [42]
Major EC bleeding 0.039 (0.007) *
CTEPH (per 3-month cycle) 0.025 (0.020) Condliffe 2008 [43]
  1. *Data are from EINSTEIN DVT or EINSTEIN PE unless otherwise stated [25,26].
  2. CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; EC, extracranial; HR, hazard ratio; IC, intracranial; NMCR, non-major clinically relevant; PE, pulmonary embolism; PTS, post-thrombotic syndrome; RR, relative risk; SE, standard error; VTE, venous thromboembolism.